{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:21:29Z","timestamp":1794032489783,"version":"4.8.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.eururo.2016.05.041","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T15:07:35Z","timestamp":1466435255000},"page":"447-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1535,"title":["EAU Guidelines on Non\u2013Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016"],"prefix":"10.1016","volume":"71","author":[{"given":"Marko","family":"Babjuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"B\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Zigeuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.05.041_bib0625","series-title":"GLOBOCAN 2012 v.1.0, estimated cancer incidence, mortality and prevalence worldwide in 2012.","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.eururo.2016.05.041_bib0630","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0635","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","article-title":"International variations in bladder cancer incidence and mortality","volume":"66","author":"Chavan","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0640","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2016.05.041_bib0645","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/bjc.2012.112","article-title":"Occupational cancer burden in Great Britain","volume":"107","author":"Rushton","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2016.05.041_bib0650","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ijc.28693","article-title":"Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai","volume":"135","author":"Corral","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2016.05.041_bib0655","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/ijc.25592","article-title":"Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"128","author":"Ros","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2016.05.041_bib0660","series-title":"UICC International Union Against Cancer","first-page":"262","article-title":"TNM classification of malignant tumors","year":"2009"},{"key":"10.1016\/j.eururo.2016.05.041_bib0665","series-title":"Histologic typing of urinary bladder tumors. International Histological Classification of Tumors, No. 10.","author":"Mostofi","year":"1973"},{"key":"10.1016\/j.eururo.2016.05.041_bib0670","series-title":"Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization classification of tumours.","year":"2004"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2016.05.041_bib0675","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib0680","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-5347(05)64553-3","article-title":"Interobserver discrepancy using the 1998 World Health Organization\/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care","volume":"168","author":"Murphy","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0685","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0690","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer","volume":"106","author":"van Rhijn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0695","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/his.12214","article-title":"An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps","volume":"63","author":"Comp\u00e9rat","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2016.05.041_bib0700","doi-asserted-by":"crossref","first-page":"e83192","DOI":"10.1371\/journal.pone.0083192","article-title":"Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder","volume":"9","author":"Mangrud","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2016.05.041_bib0705","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.juro.2009.08.083","article-title":"Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer","volume":"182","author":"Cho","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib0715","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1007\/s00330-006-0386-z","article-title":"Understanding multislice CT urography techniques: many roads lead to Rome","volume":"16","author":"Nolte-Ernsting","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0720","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0725","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2016.05.041_bib0735","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"Tetu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0740","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2016.05.041_bib0745","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib0750","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0755","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0760","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1464-410X.2009.08417.x","article-title":"Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief?","volume":"104","author":"Aaronson","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0765","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/j.1464-410X.2011.10904.x","article-title":"The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer","volume":"110","author":"Richterstetter","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0770","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-410X.2008.07966.x","article-title":"Quality control in transurethral resection of bladder tumours","volume":"102","author":"Herr","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0775","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0780","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","article-title":"Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience","volume":"57","author":"Mariappan","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0785","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2011.10571.x","volume":"109","author":"Mariappan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0790","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0795","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urpr.2014.07.001","article-title":"TaG1 bladder cancer: a third of all primary tumors and 80% of all recurrences can be treated in the office using local anesthesia","volume":"1","author":"Sabir","year":"2014","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2016.05.041_bib0800","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1464-410X.2010.09903.x","article-title":"Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience","volume":"108","author":"Gupta","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0805","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2013.12.004","article-title":"Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial","volume":"191","author":"Venkatramani","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0810","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0815","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-2042.2008.02241.x","article-title":"Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases","volume":"16","author":"Hara","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0820","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0825","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eururo.2016.05.041_bib0835","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.urolonc.2014.04.005","article-title":"Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology","volume":"32","author":"Neuzillet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0840","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0845","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2009.10.030","article-title":"Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study","volume":"57","author":"Schumacher","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0850","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.25523","article-title":"Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial","volume":"117","author":"Stenzl","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2016.05.041_bib0855","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0860","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/bju.12355","volume":"112","author":"O\u2019Brien","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0865","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1111\/j.1464-410X.2012.11500.x","article-title":"Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis","volume":"110","author":"Zheng","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0870","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0875","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000353089","article-title":"Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center","volume":"92","author":"Lazica","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib0880","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0885","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0890","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.5489\/cuaj.1514","article-title":"Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer","volume":"8","author":"Bishr","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2016.05.041_bib0895","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2003.09.018","article-title":"Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0900","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0905","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Gu\u00e9rin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0910","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0915","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non\u2013muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0920","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/01.ju.0000091800.15071.52","article-title":"Carcinoma in a bladder diverticulum: presentation and treatment outcome","volume":"170","author":"Golijanin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0925","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib0930","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2016.05.041_bib0935","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Gu\u00e9rin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0940","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0945","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0950","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2011.07.010","article-title":"Smoking status is a risk factor for recurrence after transurethral resection of non\u2013muscle-invasive bladder cancer","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0955","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.08.057","article-title":"Smoking reduces the efficacy of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy in non-muscle-invasive bladder cancer","volume":"62","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0960","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0965","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0970","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2016.05.041_bib0975","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non\u2013muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0980","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5347(05)65468-7","article-title":"Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo","volume":"167","author":"Bohle","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0985","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta,T1 bladder cancer patients. Is it always safe?","volume":"46","author":"Oddens","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0990","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib0995","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1000","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2016.05.041_bib1005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2016.05.041_bib1010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"Giesbers","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1015","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non\u2013muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib1040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib1045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib1050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1065","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib1075","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Gu\u00e9rin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1085","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC Genito-Urinary Group Study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1090","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder cancer and asymptomatic bacteriuria","volume":"187","author":"Herr","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1110","first-page":"591","article-title":"Practical guideline for the management of adverse events associated with BCG installations [in Spanish]","volume":"61","author":"Rodriguez","year":"2008","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy\u2013associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2016.05.041_bib1120","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non\u2013muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Martinez-Pineiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1135","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1140","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Gu\u00e9rin (27mg) versus very low-dose bacillus Calmette-Gu\u00e9rin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"Jarvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Gu\u00e9rin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1165","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2016.05.041_bib1170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.05.041_bib1175","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1180","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Gu\u00e9rin failure in non\u2013muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","article-title":"A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gu\u00e9rin therapy","volume":"104","author":"Barlow","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib1190","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Gu\u00e9rin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1195","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1200","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2016.05.041_bib1205","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","article-title":"Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome","volume":"110","author":"Turker","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.05.041_bib1210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","article-title":"Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1220","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)66443-9","article-title":"Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy","volume":"165","author":"Holmang","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1230","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1235","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.05.041_bib1240","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Gu\u00e9rin-treated patients continue after five tumour-free years?","volume":"61","author":"Holmang","year":"2012","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816302494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816302494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:57Z","timestamp":1759583097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816302494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0302283816302494"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU Guidelines on Non\u2013Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}